Újszülöttkori cytomegalovirus-fertozés kezelése ganciclovirrel

Translated title of the contribution: Ganciclovir treatment of congenital cytomegalovirus infection

Ágnes Till, Barnabás Rózsai, Nóra Kovács, Judit Storcz, F. Somogyvári, Judit Deák, Tibor Ertl, T. Decsi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The authors present the cases of two infants with congenital cytomegalovirus infection, who to the best of the authors'knowledge were the first ones to receive ganciclovir treatment in Hungary. Both infants were treated for symptomatic congenital cytomegalovirus infection affecting the central nervous system. Ganciclovir was given intravenously in two phases, for a total of 4 and 6 weeks, in a daily dose of 5-10 mg/kg. Diagnosis of infection and follow-up of treatment efficacy was based on the quantitative assesment by PCR assay of viral nucleic acid in blood and urine samples. Treatment resulted in substantial reduction of viral copy numbers in both infants' blood and urine samples. Improvement in the biochemical markers of disease activity was accompanied with spectacular improvement of clinical symptoms in the infant with severe liver involvement. Following the treatment viral loads increased in both infant but clinical symptoms did not reoccur. In one patient a considerable improvement of hearing loss was observed. The authors' first results indicate that ganciclovir treatment of neonatal cytomegalovirus infection represents a promising approach in preventing the progression of the disease and in ameliorating the cosequences.

Original languageHungarian
Pages (from-to)609-612
Number of pages4
JournalOrvosi Hetilap
Volume147
Issue number13
Publication statusPublished - Apr 2 2006

Fingerprint

Ganciclovir
Cytomegalovirus Infections
Urine
Therapeutics
Hungary
Viral Load
Hearing Loss
Nucleic Acids
Disease Progression
Central Nervous System
Biomarkers
Polymerase Chain Reaction
Liver
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Till, Á., Rózsai, B., Kovács, N., Storcz, J., Somogyvári, F., Deák, J., ... Decsi, T. (2006). Újszülöttkori cytomegalovirus-fertozés kezelése ganciclovirrel. Orvosi Hetilap, 147(13), 609-612.

Újszülöttkori cytomegalovirus-fertozés kezelése ganciclovirrel. / Till, Ágnes; Rózsai, Barnabás; Kovács, Nóra; Storcz, Judit; Somogyvári, F.; Deák, Judit; Ertl, Tibor; Decsi, T.

In: Orvosi Hetilap, Vol. 147, No. 13, 02.04.2006, p. 609-612.

Research output: Contribution to journalArticle

Till, Á, Rózsai, B, Kovács, N, Storcz, J, Somogyvári, F, Deák, J, Ertl, T & Decsi, T 2006, 'Újszülöttkori cytomegalovirus-fertozés kezelése ganciclovirrel', Orvosi Hetilap, vol. 147, no. 13, pp. 609-612.
Till Á, Rózsai B, Kovács N, Storcz J, Somogyvári F, Deák J et al. Újszülöttkori cytomegalovirus-fertozés kezelése ganciclovirrel. Orvosi Hetilap. 2006 Apr 2;147(13):609-612.
Till, Ágnes ; Rózsai, Barnabás ; Kovács, Nóra ; Storcz, Judit ; Somogyvári, F. ; Deák, Judit ; Ertl, Tibor ; Decsi, T. / Újszülöttkori cytomegalovirus-fertozés kezelése ganciclovirrel. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 13. pp. 609-612.
@article{968d4f408a6345dfbe2c42fe912d63d4,
title = "{\'U}jsz{\"u}l{\"o}ttkori cytomegalovirus-fertoz{\'e}s kezel{\'e}se ganciclovirrel",
abstract = "The authors present the cases of two infants with congenital cytomegalovirus infection, who to the best of the authors'knowledge were the first ones to receive ganciclovir treatment in Hungary. Both infants were treated for symptomatic congenital cytomegalovirus infection affecting the central nervous system. Ganciclovir was given intravenously in two phases, for a total of 4 and 6 weeks, in a daily dose of 5-10 mg/kg. Diagnosis of infection and follow-up of treatment efficacy was based on the quantitative assesment by PCR assay of viral nucleic acid in blood and urine samples. Treatment resulted in substantial reduction of viral copy numbers in both infants' blood and urine samples. Improvement in the biochemical markers of disease activity was accompanied with spectacular improvement of clinical symptoms in the infant with severe liver involvement. Following the treatment viral loads increased in both infant but clinical symptoms did not reoccur. In one patient a considerable improvement of hearing loss was observed. The authors' first results indicate that ganciclovir treatment of neonatal cytomegalovirus infection represents a promising approach in preventing the progression of the disease and in ameliorating the cosequences.",
keywords = "Congenital cytomegalovirus infection, Ganciclovir, Quantitative PCR",
author = "{\'A}gnes Till and Barnab{\'a}s R{\'o}zsai and N{\'o}ra Kov{\'a}cs and Judit Storcz and F. Somogyv{\'a}ri and Judit De{\'a}k and Tibor Ertl and T. Decsi",
year = "2006",
month = "4",
day = "2",
language = "Hungarian",
volume = "147",
pages = "609--612",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "13",

}

TY - JOUR

T1 - Újszülöttkori cytomegalovirus-fertozés kezelése ganciclovirrel

AU - Till, Ágnes

AU - Rózsai, Barnabás

AU - Kovács, Nóra

AU - Storcz, Judit

AU - Somogyvári, F.

AU - Deák, Judit

AU - Ertl, Tibor

AU - Decsi, T.

PY - 2006/4/2

Y1 - 2006/4/2

N2 - The authors present the cases of two infants with congenital cytomegalovirus infection, who to the best of the authors'knowledge were the first ones to receive ganciclovir treatment in Hungary. Both infants were treated for symptomatic congenital cytomegalovirus infection affecting the central nervous system. Ganciclovir was given intravenously in two phases, for a total of 4 and 6 weeks, in a daily dose of 5-10 mg/kg. Diagnosis of infection and follow-up of treatment efficacy was based on the quantitative assesment by PCR assay of viral nucleic acid in blood and urine samples. Treatment resulted in substantial reduction of viral copy numbers in both infants' blood and urine samples. Improvement in the biochemical markers of disease activity was accompanied with spectacular improvement of clinical symptoms in the infant with severe liver involvement. Following the treatment viral loads increased in both infant but clinical symptoms did not reoccur. In one patient a considerable improvement of hearing loss was observed. The authors' first results indicate that ganciclovir treatment of neonatal cytomegalovirus infection represents a promising approach in preventing the progression of the disease and in ameliorating the cosequences.

AB - The authors present the cases of two infants with congenital cytomegalovirus infection, who to the best of the authors'knowledge were the first ones to receive ganciclovir treatment in Hungary. Both infants were treated for symptomatic congenital cytomegalovirus infection affecting the central nervous system. Ganciclovir was given intravenously in two phases, for a total of 4 and 6 weeks, in a daily dose of 5-10 mg/kg. Diagnosis of infection and follow-up of treatment efficacy was based on the quantitative assesment by PCR assay of viral nucleic acid in blood and urine samples. Treatment resulted in substantial reduction of viral copy numbers in both infants' blood and urine samples. Improvement in the biochemical markers of disease activity was accompanied with spectacular improvement of clinical symptoms in the infant with severe liver involvement. Following the treatment viral loads increased in both infant but clinical symptoms did not reoccur. In one patient a considerable improvement of hearing loss was observed. The authors' first results indicate that ganciclovir treatment of neonatal cytomegalovirus infection represents a promising approach in preventing the progression of the disease and in ameliorating the cosequences.

KW - Congenital cytomegalovirus infection

KW - Ganciclovir

KW - Quantitative PCR

UR - http://www.scopus.com/inward/record.url?scp=33646942500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646942500&partnerID=8YFLogxK

M3 - Article

C2 - 16623443

AN - SCOPUS:33646942500

VL - 147

SP - 609

EP - 612

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 13

ER -